LENZ Therapeutics Inc (LENZ)

Form 8-K - Current report

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”...

LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid...

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for...